RxDoctor Payments Data

Sara Hellberg

Nurse Practitioner · Walla Walla, WANPI 1174576094

Payments from drug & device makers

$1,452in general payments, 2019–2025

Across 20 payments — averaging $72.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$296
  • Abbott$246
  • Medtronic$238
  • Abiomed$204
  • Novartis$151
  • AstraZeneca$129
  • plus $189 from 3 others

What the payments were for

  • Food & beverage$1,43899%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim5$296
Abbott2$246
Medtronic2$238
Abiomed2$204
Novartis2$151
AstraZeneca2$129
Pfizer2$106
Biotronik Inc.1$46
Novo Nordisk2$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,452 in reported general payments places this provider in the 90th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$154,077
Medicare patients
526
Services billed
1,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$273,932
EntrestoSacubitril/Valsartan71$89,629
XareltoRivaroxaban57$72,264
FarxigaDapagliflozin Propanediol62$67,095
JardianceEmpagliflozin47$48,502
MultaqDronedarone Hcl28$45,815
Repatha SureclickEvolocumab23$15,251
Metoprolol Succinate538$9,278
Potassium Chloride235$5,558
Dofetilide33$5,180
Rosuvastatin Calcium308$4,881
Verapamil SrVerapamil Hcl23$3,969
Atorvastatin Calcium220$2,755
Diltiazem 24hr ErDiltiazem Hcl62$2,347
Flecainide Acetate55$2,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$273,932205 claims
NovartisEntresto$151$89,62971 claims
AstraZenecaFarxiga$129$67,09562 claims
Boehringer IngelheimJardiance$296$48,50247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Walla Walla

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →